Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS
Contenido archivado el 2024-04-30

Biopterin-based inhibitors of nitric oxide synthase

Objetivo



Excessive NO causes tissue damage in diseases of unmet medical need such as stroke, arthritis and diabetes. Induction of Type II NOS contributes importantly to cytotoxicity and bystander damage in these pathological states. Current inhibitors are mainly arginine mimics and show limited selectivity for type II NOS over the constitutive Type I and Type III isoforms and have side effects. Synthesis of inhibitors of the binding of tetrahydrobiopterin, a cofactor requires by the enzyme, by means of non-pterin moieties which also bind haem to provide a possibly unique "selectivity signature" for NOS is proposed as a novel approach to selective NOS inhibition. Suitable leads are available in 7-nitroindazole and in phenylimidazole isomers, and data for pterins suggest that the tetrahydrobiopterin binding sites of the NOS isoforms may be distinguishable. In addition, because of its high level of expression, Type II NOS may be particularly susceptible to this form of inhibition.

Ámbito científico (EuroSciVoc)

Programa(s)

Tema(s)

Convocatoria de propuestas

Datos no disponibles

Régimen de financiación

RGI - Research grants (individual fellowships)

Coordinador

SmithKline Beecham Pharmaceuticals Ltd.
Aportación de la UE
Sin datos
Dirección
Great West Road
TW8 9EP Brentford
Reino Unido
Coste total
Sin datos

Participantes (1)